About   Help   FAQ
Phenotypes associated with this allele
Allele Symbol
Allele Name
Allele ID
Tg(Tyr-cre/ERT2)1Lru
transgene insertion 1, Lionel Larue
MGI:3617509
Summary 6 genotypes
Jump to Allelic Composition Genetic Background Genotype ID
cn1
Braftm1Mmcm/Braf+
Ptentm1Mro/Ptentm1Mro
Tg(Tyr-cre/ERT2)1Lru/0
B6.Cg-Braftm1Mmcm Ptentm1Mro Tg(Tyr-cre/ERT2)1Lru MGI:5447169
cn2
Braftm1Cpri/Braftm1Cpri
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Tg(Tyr-cre/ERT2)1Lru/0
involves: 129/Sv * 129P2/OlaHsd * C57BL/6 * DBA/2 * SJL MGI:3843342
cn3
Braftm1Cpri/Braftm1Cpri
Tg(Tyr-cre/ERT2)1Lru/0
involves: 129P2/OlaHsd * C57BL/6 * DBA/2 MGI:3843341
cn4
Braftm1Rima/Braf+
Krastm4Tyj/Kras+
Tg(Tyr-cre/ERT2)1Lru/0
involves: 129S4/SvJae * C57BL/6 * DBA/2 MGI:4458349
cn5
Braftm1Rima/Braf+
Tg(Tyr-cre/ERT2)1Lru/0
involves: C57BL/6 * DBA/2 MGI:4458350
cn6
Braftm1Rima/Braf+
Tg(GFP/KRAS2/ALPP)1Brn/0
Tg(Tyr-cre/ERT2)1Lru/0
involves: C57BL/6 * DBA/2 * FVB/N MGI:4458351


Genotype
MGI:5447169
cn1
Allelic
Composition
Braftm1Mmcm/Braf+
Ptentm1Mro/Ptentm1Mro
Tg(Tyr-cre/ERT2)1Lru/0
Genetic
Background
B6.Cg-Braftm1Mmcm Ptentm1Mro Tg(Tyr-cre/ERT2)1Lru
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Braftm1Mmcm mutation (2 available); any Braf mutation (20 available)
Ptentm1Mro mutation (1 available); any Pten mutation (37 available)
Tg(Tyr-cre/ERT2)1Lru mutation (0 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• tamoxifen-treated mice must be euthanized between 40 and 70 days due to tumor load or ulceration (J:188523)
• tamoxifen-treated mice must be euthanized between 40 and 70 days due to tumor load or ulceration (J:188523)

tumorigenesis
• tamoxifen-treated mice develop multiple heavily pigmented papules with an average latency of 18 days (J:188523)
• tamoxifen-treated mice exhibit metastasis in draining lymph nodes as early as 4 weeks after tumor induction (J:188523)
• however, no visceral metastasis is observed (J:188523)
• however, treatment with PLX4720 decreases tumor outgrowth (J:188523)
• in the absences of tamoxifen, most mice develop spontaneous melanomas due to leaky cre expression (J:188523)
• tamoxifen-treated mice develop multiple heavily pigmented papules with an average latency of 18 days (J:188523)
• tamoxifen-treated mice exhibit metastasis in draining lymph nodes as early as 4 weeks after tumor induction (J:188523)
• however, no visceral metastasis is observed (J:188523)
• however, treatment with PLX4720 decreases tumor outgrowth (J:188523)
• in the absences of tamoxifen, most mice develop spontaneous melanomas due to leaky cre expression (J:188523)

integument
• in tamoxifen-treated mice (J:188523)
• in tamoxifen-treated mice (J:188523)
• tamoxifen-treated mice develop multiple heavily pigmented papules with an average latency of 18 days (J:188523)
• tamoxifen-treated mice exhibit metastasis in draining lymph nodes as early as 4 weeks after tumor induction (J:188523)
• however, no visceral metastasis is observed (J:188523)
• however, treatment with PLX4720 decreases tumor outgrowth (J:188523)
• in the absences of tamoxifen, most mice develop spontaneous melanomas due to leaky cre expression (J:188523)
• tamoxifen-treated mice develop multiple heavily pigmented papules with an average latency of 18 days (J:188523)
• tamoxifen-treated mice exhibit metastasis in draining lymph nodes as early as 4 weeks after tumor induction (J:188523)
• however, no visceral metastasis is observed (J:188523)
• however, treatment with PLX4720 decreases tumor outgrowth (J:188523)
• in the absences of tamoxifen, most mice develop spontaneous melanomas due to leaky cre expression (J:188523)

Mouse Models of Human Disease
OMIM ID Ref(s)
Melanoma, Cutaneous Malignant, Susceptibility to, 1; CMM1 155600 J:188523




Genotype
MGI:3843342
cn2
Allelic
Composition
Braftm1Cpri/Braftm1Cpri
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Tg(Tyr-cre/ERT2)1Lru/0
Genetic
Background
involves: 129/Sv * 129P2/OlaHsd * C57BL/6 * DBA/2 * SJL
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Braftm1Cpri mutation (0 available); any Braf mutation (20 available)
Cdkn2atm1Rdp mutation (5 available); any Cdkn2a mutation (26 available)
Tg(Tyr-cre/ERT2)1Lru mutation (0 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
tumorigenesis
• tamoxifen-treated mice develop multiple tumors unlike Braftm1Cpri/Braftm1Cpri Tg(Tyr-cre/ERT2)1Laru mice that develop single tumors (J:147434)
• tamoxifen-treated mice develop multiple tumors unlike Braftm1Cpri/Braftm1Cpri Tg(Tyr-cre/ERT2)1Laru mice that develop single tumors (J:147434)
• tamoxifen-treated mice develop nevi unlike control mice (either treated with only ethanol or lacking one of the alleles) (J:147434)
• tamoxifen-treated mice develop nevi unlike control mice (either treated with only ethanol or lacking one of the alleles) (J:147434)
• 80% of tamoxifen-treated mice develop melanomas within 12 months (J:147434)
• median latency to develop melanomas in a tamoxifen-treated mouse is 7 months (J:147434)
• 80% of tamoxifen-treated mice develop melanomas within 12 months (J:147434)
• median latency to develop melanomas in a tamoxifen-treated mouse is 7 months (J:147434)

integument
• tamoxifen-treated mice develop nevi unlike control mice (either treated with only ethanol or lacking one of the alleles) (J:147434)
• tamoxifen-treated mice develop nevi unlike control mice (either treated with only ethanol or lacking one of the alleles) (J:147434)

homeostasis/metabolism
• tamoxifen-treated mice develop multiple tumors unlike Braftm1Cpri/Braftm1Cpri Tg(Tyr-cre/ERT2)1Laru mice that develop single tumors (J:147434)
• tamoxifen-treated mice develop multiple tumors unlike Braftm1Cpri/Braftm1Cpri Tg(Tyr-cre/ERT2)1Laru mice that develop single tumors (J:147434)




Genotype
MGI:3843341
cn3
Allelic
Composition
Braftm1Cpri/Braftm1Cpri
Tg(Tyr-cre/ERT2)1Lru/0
Genetic
Background
involves: 129P2/OlaHsd * C57BL/6 * DBA/2
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Braftm1Cpri mutation (0 available); any Braf mutation (20 available)
Tg(Tyr-cre/ERT2)1Lru mutation (0 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
tumorigenesis
• tamoxifen-treated mice develop nevi most commonly at the site of application with some large melanocytic lesions around the perianal regions and in the eyelids unlike in control mice (either treated with only ethanol or lacking one of the alleles) (J:147434)
• nevi in tamoxifen-treated mice are slowly proliferating, dome-shaped outgrowths in the dermis composed of pigmented epithelioid or dendritic melanocytes with neuroid differentiation in some cases (J:147434)
• 80% of tamoxifen-treated mice develop eyelid nevi 3 to 5 months after treatment (J:147434)
• mice treated with high doses of tamoxifen develop perianal nevi 6 to 10 months after treatment (J:147434)
• 60% to 70% of tamoxifen-treated mice develop rapidly growing, invasive hypopigmented skin tumors that often (in 38% of mice) ulcerate the overlying epidermis, infiltrate the subcutis, skeletal muscle, and auricular cartilage and display characteristics of malignant melanomas (J:147434)
• tamoxifen-treated mice develop nevi most commonly at the site of application with some large melanocytic lesions around the perianal regions and in the eyelids unlike in control mice (either treated with only ethanol or lacking one of the alleles) (J:147434)
• nevi in tamoxifen-treated mice are slowly proliferating, dome-shaped outgrowths in the dermis composed of pigmented epithelioid or dendritic melanocytes with neuroid differentiation in some cases (J:147434)
• 80% of tamoxifen-treated mice develop eyelid nevi 3 to 5 months after treatment (J:147434)
• mice treated with high doses of tamoxifen develop perianal nevi 6 to 10 months after treatment (J:147434)
• 60% to 70% of tamoxifen-treated mice develop rapidly growing, invasive hypopigmented skin tumors that often (in 38% of mice) ulcerate the overlying epidermis, infiltrate the subcutis, skeletal muscle, and auricular cartilage and display characteristics of malignant melanomas (J:147434)
• some tamoxifen-treated mice develop oligomelanotic malignant melanomas unlike control mice (either treated with only ethanol or lacking one of the alleles) (J:147434)
• 54% of tamoxifen-treated mice develop melanomas within 12 months (J:147434)
• 64% of tamoxifen-treated mice develop melanomas after 14 months (J:147434)
• median latency to develop melanomas in a tamoxifen-treated mouse is 12 months (J:147434)
• some tamoxifen-treated mice develop oligomelanotic malignant melanomas unlike control mice (either treated with only ethanol or lacking one of the alleles) (J:147434)
• 54% of tamoxifen-treated mice develop melanomas within 12 months (J:147434)
• 64% of tamoxifen-treated mice develop melanomas after 14 months (J:147434)
• median latency to develop melanomas in a tamoxifen-treated mouse is 12 months (J:147434)

pigmentation
• following application of tamoxifen on the back, snouts, tails, ears, and paws are visibly darkened compared to in control mice (either treated with only ethanol or lacking one of the alleles) (J:147434)
• following application of tamoxifen on the back, 40% of mice develop darkened toenails proximal to the body on the front or hind feet unlike control mice (J:147434)
• following application of tamoxifen on the back, 50% of females develop darkened nipples unlike control mice (J:147434)
• following application of tamoxifen on the back, hairy skin is darkened most noticeable at the site of application unlike control mice (J:147434)
• following application of tamoxifen on the back, snouts, tails, ears, and paws are visibly darkened compared to in control mice (either treated with only ethanol or lacking one of the alleles) (J:147434)
• following application of tamoxifen on the back, 40% of mice develop darkened toenails proximal to the body on the front or hind feet unlike control mice (J:147434)
• following application of tamoxifen on the back, 50% of females develop darkened nipples unlike control mice (J:147434)
• following application of tamoxifen on the back, hairy skin is darkened most noticeable at the site of application unlike control mice (J:147434)

integument
• in 38% of tamoxifen-treated mice (J:147434)
• in 38% of tamoxifen-treated mice (J:147434)
• tamoxifen-treated mice develop nevi most commonly at the site of application with some large melanocytic lesions around the perianal regions and in the eyelids unlike in control mice (either treated with only ethanol or lacking one of the alleles) (J:147434)
• nevi in tamoxifen-treated mice are slowly proliferating, dome-shaped outgrowths in the dermis composed of pigmented epithelioid or dendritic melanocytes with neuroid differentiation in some cases (J:147434)
• 80% of tamoxifen-treated mice develop eyelid nevi 3 to 5 months after treatment (J:147434)
• mice treated with high doses of tamoxifen develop perianal nevi 6 to 10 months after treatment (J:147434)
• 60% to 70% of tamoxifen-treated mice develop rapidly growing, invasive hypopigmented skin tumors that often (in 38% of mice) ulcerate the overlying epidermis, infiltrate the subcutis, skeletal muscle, and auricular cartilage and display characteristics of malignant melanomas (J:147434)
• tamoxifen-treated mice develop nevi most commonly at the site of application with some large melanocytic lesions around the perianal regions and in the eyelids unlike in control mice (either treated with only ethanol or lacking one of the alleles) (J:147434)
• nevi in tamoxifen-treated mice are slowly proliferating, dome-shaped outgrowths in the dermis composed of pigmented epithelioid or dendritic melanocytes with neuroid differentiation in some cases (J:147434)
• 80% of tamoxifen-treated mice develop eyelid nevi 3 to 5 months after treatment (J:147434)
• mice treated with high doses of tamoxifen develop perianal nevi 6 to 10 months after treatment (J:147434)
• 60% to 70% of tamoxifen-treated mice develop rapidly growing, invasive hypopigmented skin tumors that often (in 38% of mice) ulcerate the overlying epidermis, infiltrate the subcutis, skeletal muscle, and auricular cartilage and display characteristics of malignant melanomas (J:147434)




Genotype
MGI:4458349
cn4
Allelic
Composition
Braftm1Rima/Braf+
Krastm4Tyj/Kras+
Tg(Tyr-cre/ERT2)1Lru/0
Genetic
Background
involves: 129S4/SvJae * C57BL/6 * DBA/2
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Braftm1Rima mutation (0 available); any Braf mutation (20 available)
Krastm4Tyj mutation (4 available); any Kras mutation (30 available)
Tg(Tyr-cre/ERT2)1Lru mutation (0 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
tumorigenesis
• within 6 months, tamoxifen-treated mice develop large, rapid growing oligo-pigmented tumors with ulceration unlike wild-type mice (J:161180)
• tumors in tamoxifen-treated mice are largely composed of spindle cells with malignancy features (J:161180)
• within 6 months, tamoxifen-treated mice develop large, rapid growing oligo-pigmented tumors with ulceration unlike wild-type mice (J:161180)
• tumors in tamoxifen-treated mice are largely composed of spindle cells with malignancy features (J:161180)

pigmentation
• within 2 to 3 months, tamoxifen-treated mice exhibit a darkening of the tails, ears, and paws compared with wild-type mice (J:161180)
• within 2 to 3 months, tamoxifen-treated mice exhibit a darkening of the tails, ears, and paws compared with wild-type mice (J:161180)




Genotype
MGI:4458350
cn5
Allelic
Composition
Braftm1Rima/Braf+
Tg(Tyr-cre/ERT2)1Lru/0
Genetic
Background
involves: C57BL/6 * DBA/2
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Braftm1Rima mutation (0 available); any Braf mutation (20 available)
Tg(Tyr-cre/ERT2)1Lru mutation (0 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
pigmentation
N
• mice exhibit normal pigmentation and do not develop nevi (J:161180)
• mice exhibit normal pigmentation and do not develop nevi (J:161180)

tumorigenesis
N
• mice do not develop tumors (J:161180)
• mice do not develop tumors (J:161180)




Genotype
MGI:4458351
cn6
Allelic
Composition
Braftm1Rima/Braf+
Tg(GFP/KRAS2/ALPP)1Brn/0
Tg(Tyr-cre/ERT2)1Lru/0
Genetic
Background
involves: C57BL/6 * DBA/2 * FVB/N
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Braftm1Rima mutation (0 available); any Braf mutation (20 available)
Tg(GFP/KRAS2/ALPP)1Brn mutation (1 available)
Tg(Tyr-cre/ERT2)1Lru mutation (0 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
tumorigenesis
• tamoxifen-treated mice exhibit rapid onset of melanoma with a median onset at 2 months and 100% penetrance within 3 months (J:161180)
• tamoxifen-treated mice exhibit rapid onset of melanoma with a median onset at 2 months and 100% penetrance within 3 months (J:161180)





Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Tumor Biology (MTB), Gene Ontology (GO), MouseCyc
Citing These Resources
Funding Information
Warranty Disclaimer & Copyright Notice
Send questions and comments to User Support.
last database update
02/02/2016
MGI 6.02
The Jackson Laboratory